Current Event-Free Survival After Sequential Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia

Cancer - United States
doi 10.1002/cncr.25604
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Managing Chronic Myeloid Leukemia Patients Intolerant to Tyrosine Kinase Inhibitor Therapy

Blood Cancer Journal
OncologyHematology
2012English

Tyrosine Kinase Inhibitor Sequencing in Patients With Chronic Myeloid Leukemia

Oncology and Therapy
Oncology
2019English

Planned Pregnancy in Female Patients With Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy

Oncologist
Cancer ResearchMedicineOncology
2019English

Cognitive Dysfunction After Withdrawal of Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia

American Journal of Hematology
Hematology
2016English

Complications of Tyrosine Kinase Inhibitors Therapy in Chronic Myeloid Leukemia - Chronic Phase

Revista de Chimie
SurfacesMaterials ScienceEngineeringMaterials ChemistryFilmsCoatingsChemistry
2019English

Current Status of ABL Tyrosine Kinase Inhibitors Stop Studies for Chronic Myeloid Leukemia

Stem Cell Investigation
2016English

Outcome of Patients With Chronic Myeloid Leukemia With Multiple ABL1 Kinase Domain Mutations Receiving Tyrosine Kinase Inhibitor Therapy

Haematologica
Hematology
2011English

Stochastic Modelling of Tyrosine Kinase Inhibitor Rotation Therapy in Chronic Myeloid Leukaemia

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

Discovering Gene Expression Signatures Responding to Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia

BMC Medical Genomics
Genetics
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy